Back to rankings
England - London • TMT (technology, media and telecoms)
4

Intellectual property: patents (contentious and non-contentious)

Arnold & Porter logo

Arnold & Porter

More information
Litigator and SPC specialist Beatriz San Martin heads the life sciences-focused operation at Arnold & Porter, which has handled a long list of research and development projects, partnership, licensing, and collaboration agreements, M&A, and more for key innovators in the pharma space. Notably experienced in vaccine-related work, Ewan Townsend handles transactional mandates for a range of pharma clients, assisting with the development, exploitation, and commercialisation of medicinal products as well as delivering regulatory advice. Also on the team is Tom Wilson, who focuses on transactions.
Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘Ewan Townsend is excellent.’

  • ‘They are very approachable and build strong relationships with clients.’

  • ‘They not only give excellent strategic and commercial advice, but do so in a straightforward way.’

  • ‘Ewan Townsend and Beatriz San Martin provide a truly one-stop shop for those within the life sciences and biotech sectors needing support with contentious or non-contentious patent queries. They are commercial, technically excellent, and hugely experienced, alongside being very pleasant to work with generally.’

  • ‘Ewan Townsend is a standout practitioner in terms of providing very sound legal and commercial support to clients. He is additionally brilliant to work with and inspires absolute confidence from the client perspective.'

Key clients

  • Cognizant
  • Pfizer
  • Touchlight
  • Norgine
  • Essential Pharma
  • AstraZeneca
  • Alnylam
  • Amicus

Work highlights

Advising Touchlight on an agreement and a long-term collaboration for the development and manufacture of new dbDNA vaccines and therapeutics across a broad range of animal health indications.
Advising Norgine on an exclusive license with Fennec Pharmaceuticals in respect of PEDMARQSI®, the only approved therapy in the EU and U.K. for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to 18 years of age with localised, non-metastatic solid tumours.
Advising AstraZeneca on a new framework agreement under which CEPI will provide funding of up to $45m for the development of vaccines, biologics, or other medical counter-measures, including a multi-specific pandemic influenza vaccine utilising AZ’s proprietary VHH antibody platform.

Practice head

Beatriz San Martin

Other key lawyers

Ewan Townsend; Tom Wilson